DGKA and schizophrenia: Of the DGKα (and 5-HT2A/2C serotonin receptor) inhibitors we analysed, only ritanserin has been tested in human clinicals trials, but in the context of schizophrenia, cocaine and alcohol dependence, and migraines (Cornish et al., 2001; Johnson et al., 1996; Nappi et al., 1990; Wiesel et al., 1994), and it has not been marketed for clinical use.